Korro Bio, Inc. KRRO · Stock Open Korro Bio, Inc. in new tab
Analyst price targets
Recent rating changes, newest first
Korro Bio, Inc. Analysis (KRRO)
Is Korro Bio, Inc. a good investment? Korro Bio, Inc. (KRRO) is currently trading at 10.16 USD. Market analysts have a consensus price target of 20.20 USD. This suggests a potential upside from current levels.
Earnings Schedule: Korro Bio, Inc. is expected to release its next earnings report on Nov. 11, 2026. The market consensus estimate for Forward EPS is -4.42.
Investor FAQ
Does Korro Bio, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Korro Bio, Inc.?
Korro Bio, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Nov. 11, 2026. The company currently has a trailing EPS of -9.50.
Company Profile
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
| Split Date | Split Ratio to 1 |
|---|---|
| Nov. 6, 2023 | 1:50 |
Community Discussion